Geron Corporation
Geron Corporation
Your view on GERN
Overview
What the company does, where it operates, and who runs it.
About Geron Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Harout Semerjian
- Headquarters
- 919 East Hillsdale Boulevard, Foster City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Harout Semerjian
- Headquarters
- 919 East Hillsdale Boulevard, Foster City, CA, US
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Geron Corporation from FRC's valuation model, read against the market price. GERN last traded at $0.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Geron Corporation. Starting points for Geron Corporation: EPS -$0.07, beta 0.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Geron Corporation. Geron Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Geron Corporation. Trailing twelve-month EPS for Geron Corporation stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$5.89
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy15
- Hold7
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.01 | -$0.03 | $0.07 |
| Low estimate | -$0.00 | $0.01 | -$0.06 | $0.03 |
| High estimate | $0.01 | $0.01 | -$0.01 | $0.14 |
| No. of analysts | 2 | 1 | 2 | 3 |
| Year-ago EPS | -$0.03 | -$0.01 | -$0.13 | — |
| Growth | +112.5% | +187.7% | +78.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $65.50M | $68.99M | $235.32M | $320.51M |
| Low estimate | $64.92M | $67.08M | $234.67M | $318.67M |
| High estimate | $66.07M | $72.14M | $235.98M | $322.33M |
| No. of analysts | 3 | 2 | 4 | 4 |
| Year-ago revenue | $48.02M | $51.84M | $183.88M | — |
| Growth | +36.4% | +33.1% | +28.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 16, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Geron Corporation. Geron Corporation has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ATNMActinium Pharmaceuticals, Inc.Biotechnology$52M
- COAGHemab Therapeutics Holdings, Inc. Common StockBiotechnology$1.9B
- DMRADamora Therapeutics, Inc.Biotechnology$1.3B
- INCYIncyte CorporationBiotechnology$24.7B
- IPSCCentury Therapeutics, Inc.Biotechnology$299M
- RIGLRigel Pharmaceuticals, Inc.Biotechnology$837M
- SLSSELLAS Life Sciences Group, Inc.Biotechnology$1.6B
More Biotechnology companies
- SLXNWSilexion Therapeutics Ltd.NASDAQ$70,256
- SMMTSummit Therapeutics Inc.NASDAQ$11.3B
- SNANFSona Nanotech Inc.OTC$36M
- SNBIFSanBio Company LimitedOTC$1.3B
- SNDXSyndax Pharmaceuticals, Inc.NASDAQ$851M
- SNGXSoligenix, Inc.NASDAQ$8M
- SNNAQSienna Biopharmaceuticals, Inc.OTC$3,091
- SNTISenti Biosciences, Inc.NASDAQ$4M
- SOLTFNxera Pharma Co., Ltd.OTC$492M
- SONA.CNSona Nanotech Inc.CNQ$49M
- SPHDFSanthera Pharmaceuticals Holding AGOTC$295M
- SPHRFStarpharma Holdings LimitedOTC$134M
ETFs holding Geron Corporation
% of the fund
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.18%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWMiShares Russell 2000 ETF$76.6B in assets0.02%
- VXFVanguard Extended Market ETF$30.2B in assets0.01%
- BBPVirtus LifeSci Biotech Products ETF$133M in assets1.14%
- SBIOALPS Medical Breakthroughs ETF$187M in assets0.41%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.03%
- PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.03%
Largest holders first, then the funds most concentrated in GERN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Geron Corporation, and how their positions are changing. At a $623.0M market value, institutional positions materially move Geron Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Geron Corporation executives and directors. Shares of Geron Corporation have traded between $1.04 and $4.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Geron Corporation. Coverage tracks Geron Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Geron Corporation.